Jun 12, 2019 / 03:40PM GMT
Graig Suvannavejh - Goldman Sachs - Analyst
Okay, good morning, everyone, and welcome to I believe it's the 8:40 session here at the Goldman Sachs Global Healthcare Conference. By introduction, my name is Graig Suvannavejh; I cover European biotech for the Firm and I'm seated out of London. It's my pleasure to introduce DBV Technologies today. With us is CEO Daniel Tassé and in the audience is Sara Sherman who is Senior Director of Investor Relations.
Questions and Answers:
Graig Suvannavejh - Goldman Sachs - AnalystSo with that, Daniel, you are new to the company, CEO. Maybe if you could just tell us your thought process when you were thinking about opportunities, why DBV was the one that you were compelled to join.
Daniel Tassé,DBV Technologies SA-CEO
Thank you and good morning, Graig. Look, I'm the poster child for the traditional pharmaceutical industry with a graduate degree in biochemistry, then took on commercial jobs and then after that strategy in jobs that intersect science